| 21.13 -1.02 (-4.6%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.26 | 1-year : | 31.84 |
| Resists | First : | 23.34 | Second : | 27.26 |
| Pivot price | 20.55  |
|||
| Supports | First : | 18.8 | Second : | 15.99 |
| MAs | MA(5) : | 21.92 |
MA(20) : | 19.94 |
| MA(100) : | 15.49 |
MA(250) : | 14.07 |
|
| MACD | MACD : | 1.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 71.6 |
D(3) : | 79.7 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 29.45 | Low : | 5.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ UPB ] has closed below upper band by 39.9%. Bollinger Bands are 44.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 22.43 - 22.62 | 22.62 - 22.74 |
| Low: | 20.65 - 20.84 | 20.84 - 20.97 |
| Close: | 20.88 - 21.18 | 21.18 - 21.38 |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Sat, 18 Oct 2025
Upstream Bio (UPB): Fresh Data and Analyst Coverage Spark New Questions on Valuation - Sahm
Fri, 17 Oct 2025
Upstream Bio, Inc. (UPB) Investor Outlook: Unpacking The 123% Potential Upside In Biotech - DirectorsTalk Interviews
Thu, 16 Oct 2025
Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting - Insider Monkey
Tue, 14 Oct 2025
Truist Securities Initiates Coverage on Upstream Bio (UPB) with a Buy Rating | UPB Stock News - GuruFocus
Fri, 10 Oct 2025
Why Upstream Bio (UPB) Is Up 6.5% After Positive Phase 2 Results for Verekitug in Respiratory Diseases - Sahm
Sat, 04 Oct 2025
Upstream Bio (UPB): Assessing Valuation as Shares Climb 7% Over the Past Week - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.142e+007 (%) |
| Held by Institutions | 14.8 (%) |
| Shares Short | 3,100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2142e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 732.8 % |
| Return on Equity (ttm) | -22.9 % |
| Qtrly Rev. Growth | 2.72e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -6.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 3.56e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|